Acute Myeloid Leukemia Registry
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- This is an observational study: the protocol does not assign a study treatment.
- Who it may be relevant to
- Registry conditions: Acute Myeloid Leukemia. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Turkey (Türkiye)
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Acute Myeloid Leukemia Registry - Prospective National Multicentric Observational Study
Overview
All acute myeloid leukemia (AML) patients diagnosed after 1 Jan 2020 will be included to this study.
Detailed description
This is a non interventional prospective disease registry, 250 prospective patients diagnosed with AML across 20 centers in Turkey.
Participating sites will consist of hematology clinics and routine follow-up procedures will be followed-up.
All patients diagnosed after 1 Jan 2020 as AML will be included and patients will be enrolled during 24 months of period and will be followed-up 36 months. Study will be completed in 60 months.
Primary outcome measures
- Overall Survival [Time frame: 60 months]
Eligibility criteria
Inclusion criteria
- Diagnosed as AML after 1 Jan 2020
- Patients signed informed consent form
Exclusion criteria
- Patients under 18 years old
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Cohort
Study locations
Turkey (Türkiye) · 1 center
- Antalya Training and Research Hospital — Antalya
Publications
- Karakus V, Pinar IE, Iltar U, Yenihayat EM, Polat MG, Celik S, Malkan UY, Cengiz Seval G, Dogan A, Akdeniz A, Ozbalci D, Ince I, Erdem R, Mehtap O, Kirkizlar HO, Kacmaz M, Deveci B, Aykas F, Korkmaz G, Yigit Kaya S, Afacan Ozturk HB, Sevindik OG, Can F, Cekdemir D, Aslan C, Bulbul H, Karabulut ZT, Maral S, Durusoy SS, Demirkan F, Goker H, Ozkalemkas F, Keklik M, Toprak SK, Karatas AF, Atas U, Alac PMID 41156238
- Pinar IE, Celik S, Polat MG, Karatas AF, Dogan A, Iltar U, Cengiz Seval G, Malkan UY, Ince I, Yenihayat EM, Akdeniz A, Kacmaz M, Erdem R, Afacan Ozturk HB, Kirkizlar HO, Korkmaz G, Aykas F, Mehtap O, Deveci B, Sevindik OG, Can F, Ozbalci D, Bulbul H, Durusoy SS, Atas U, Keklik M, Toprak SK, Goker H, Demirkan F, Ozkalemkas F, Alacacioglu I, Karakus V; Turkish Society of Hematology-Acute Leukemias W PMID 41073967
Identifiers
NCT: NCT05979675 · AML_Registry